Equities

Psyence Biomedical Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
PBM:NAQ

Psyence Biomedical Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.79
  • Today's Change-0.300 / -9.71%
  • Shares traded45.90k
  • 1 Year change-95.98%
  • Beta0.3432
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

  • Revenue in USD (TTM)--
  • Net income in USD--
  • Incorporated2023
  • Employees12.00
  • Location
    Psyence Biomedical Ltd121 Richmond Street West PenthouseSuite 1300TORONTO M5H 2K1CanadaCAN
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Propanc Biopharma Inc0.00-63.41m2.85m1.00--0.1976-----45.47-45.470.001.080.00----0.00-702.98---1,223.40-------------56.990.0422-------2,826.43------
Enzolytics Inc0.00-119.19k2.90m2.00---------0.106-0.1060.00-1.040.00-------369.52-----------------4.30-----100.00---9.35------
Geovax Labs Inc3.35m-25.31m2.91m17.00--0.4068--0.8677-49.15-49.155.864.130.3759--12.25197,268.20-283.68-128.86-377.44-172.81-----754.69-1,385.19----0.00----27.453.75--22.10--
Enveric Biosciences Inc0.00-11.25m2.92m5.00--0.1326-----94.63-94.630.0015.830.00----0.00-212.68-146.94-262.78-198.90------------0.00------45.16------
Shuttle Pharmaceuticals Holdings Inc0.00-10.71m2.98m9.00--0.9837-----25.86-25.860.001.130.00----0.00-507.78---3,614.50--------------0.2305-------38.71------
Dermata Therapeutics Inc0.00-8.85m3.08m8.00--0.2751-----28.37-28.370.004.690.00----0.00-150.49-136.32-203.36-201.56------------0.00-------57.64------
Psyence Biomedical Ltd-100.00bn-100.00bn3.16m12.00--0.0125----------247.64----------------------------0.00------101.98------
Adial Pharmaceuticals Inc0.00-8.05m3.17m5.00--0.6032-----23.22-23.220.004.720.00----0.00-130.16-205.76-155.01-274.10-----------27.380.00-------88.48------
ProtoKinetix, Inc.0.00-376.18k3.21m0.00--12.77-----0.001-0.0010.000.00060.00-------78.62-530.88-117.20-607.05------------0.00------12.34--18.34--
GRI Bio Inc0.00-11.96m3.34m4.00--0.1914-----248.19-248.190.0012.070.00----0.00-166.00-190.54-236.14-330.83------------0.00-------18.17--8.45--
Vaccinex Inc601.00k-18.63m3.35m23.00------5.57-9.91-9.910.2864-0.92950.193--0.668226,130.44-598.49-299.11---------3,100.50-3,700.14---149.88----5.442.827.98---22.36--
Burzynski Research Institute Inc0.00-1.29m3.42m2.00---------0.0098-0.00980.00-0.00050.00-------86,374.50-28,790.65-------------------------3.80------
National Graphite Corp0.00-1.97m3.55m0.00---------0.0221-0.02210.00-0.01930.00-------11,014.44-212.13---6,295.18---------------------1,432.70------
AIM ImmunoTech Inc112.00k-15.75m3.57m21.00------31.87-19.82-19.820.1067-2.200.0117----5,333.33-165.08-50.43-637.78-55.2315.18-113.19-14,062.50-12,238.47---------15.843.9640.20---45.22--
Data as of Feb 17 2026. Currency figures normalised to Psyence Biomedical Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.